Encore Global Management’s AbbVie ABBV Stock Holding History

Encore Global Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,500	Closed	-$544K	–	54
2026 Q1	$544K	Buy	+2,500	New	+$555K	0.38%	59

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Encore Global Management's ABBV Position: Q2 2026 in Review

Encore Global Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 2,500 shares — an estimated $544K sold.

Encore Global Management first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $544K in Q1 2026. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Encore Global Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Encore Global Management sold 2,500 AbbVie shares in Q2 2026, an estimated $544K.
Encore Global Management first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
Encore Global Management's AbbVie position peaked at $544K in Q1 2026.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Encore Global Management's 13F filing for Q2 2026, filed 11 Aug 2026.